BIIB
Price
$131.84
Change
+$0.70 (+0.53%)
Updated
Jun 3 closing price
Capitalization
31.34B
49 days until earnings call
PFE
Price
$23.43
Change
+$0.08 (+0.34%)
Updated
Jun 4, 10:41 AM (EDT)
Capitalization
157.14B
62 days until earnings call
Interact to see
Advertisement

BIIB vs PFE

Header iconBIIB vs PFE Comparison
Open Charts BIIB vs PFEBanner chart's image
Biogen
Price$131.84
Change+$0.70 (+0.53%)
Volume$1.83M
Capitalization31.34B
Pfizer
Price$23.43
Change+$0.08 (+0.34%)
Volume$25.43K
Capitalization157.14B
BIIB vs PFE Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. PFE commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and PFE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (BIIB: $131.84 vs. PFE: $23.35)
Brand notoriety: BIIB and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 102% vs. PFE: 76%
Market capitalization -- BIIB: $31.34B vs. PFE: $157.14B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, PFE is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 3 bearish.
  • PFE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than PFE.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +2.69% price change this week, while PFE (@Pharmaceuticals: Major) price change was -1.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.49%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +2.66%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 23, 2025.

PFE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+2.49% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($157B) has a higher market cap than BIIB($31.3B). PFE has higher P/E ratio than BIIB: PFE (74.92) vs BIIB (26.95). PFE YTD gains are higher at: -8.825 vs. BIIB (-13.785). PFE has higher annual earnings (EBITDA): 9.56B vs. BIIB (2.04B). PFE has more cash in the bank: 12.7B vs. BIIB (1.05B). BIIB has less debt than PFE: BIIB (7.34B) vs PFE (70.8B). PFE has higher revenues than BIIB: PFE (58.5B) vs BIIB (9.84B).
BIIBPFEBIIB / PFE
Capitalization31.3B157B20%
EBITDA2.04B9.56B21%
Gain YTD-13.785-8.825156%
P/E Ratio26.9574.9236%
Revenue9.84B58.5B17%
Total Cash1.05B12.7B8%
Total Debt7.34B70.8B10%
FUNDAMENTALS RATINGS
BIIB vs PFE: Fundamental Ratings
BIIB
PFE
OUTLOOK RATING
1..100
109
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7174
PRICE GROWTH RATING
1..100
6260
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (87) in the Biotechnology industry. This means that PFE’s stock grew significantly faster than BIIB’s over the last 12 months.

PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as PFE (74) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to PFE’s over the last 12 months.

PFE's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as BIIB (62) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

PFE's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that PFE’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBPFE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
57%
Momentum
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 1 day ago
54%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
62%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
58%
Advances
ODDS (%)
Bullish Trend 1 day ago
54%
Bullish Trend 6 days ago
56%
Declines
ODDS (%)
Bearish Trend 13 days ago
70%
Bearish Trend 1 day ago
61%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 6 days ago
60%
Aroon
ODDS (%)
Bullish Trend 1 day ago
38%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EYEN2.110.44
+26.35%
Eyenovia Inc
SQM30.820.79
+2.63%
Sociedad Quimica y Minera de Chile SA
KLIC32.970.76
+2.34%
Kulicke and Soffa Industries
FLWS4.870.06
+1.25%
1-800-FLOWERS.COM
IKT2.03-0.02
-0.98%
Inhibikase Therapeutics

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+0.53%
AMGN - BIIB
52%
Loosely correlated
+0.38%
PFE - BIIB
49%
Loosely correlated
-0.47%
NVS - BIIB
47%
Loosely correlated
-0.65%
SNY - BIIB
43%
Loosely correlated
N/A
AZN - BIIB
40%
Loosely correlated
-0.15%
More